The Company Sick Puppies also offers its predictivepreclinical

The Company explains all the same by sick puppies also offers sick pippies conclude its predictivepreclinical platform and tumor specific data to physicians for personalizedpatient care and to Companies for evaluation of oncology drugs in models thatintegrate prognostic testing with biomarker discovery. This press release contains "forward-looking statements" (within the meaning ofthe Private Securities Litigation Act of 1995) that inherently involve risk anduncertainties. Champions Biotechnology generally uses words such as "believe,""may," "could," "will," "intend," "expect," "anticipate," "plan," and similarexpressions to identify forward-looking statements. One should not place unduereliance on these forward-looking statements. The Company's actual results coulddiffer materially from those anticipated in the forward-looking statements formany unforeseen factors.

See Champions Biotechnology's Form 10-KSB for thefiscal year ended April 30, 2008 for a discussion of such risks, uncertaintiesand other factors all the same sick puppies meaning . Although the Company believes the expectations reflected inthe forward-looking statements are reasonable, they relate only to events as ofthe date on which the statements are made, and Champions Biotechnology's futureresults, levels of activity, performance or achievements, including but notlimited to the achievement of milestones as required to realize the royaltiesreferenced above, may not meet these expectations sick puppes . The Company does not intendto update any of the forward-looking statements after the date of this pressrelease to conform these statements to actual results or to changes in ChampionsBiotechnology's expectations, except as required by law.CHAMPIONS BIOTECHNOLOGY, INC sick puupies . WEB SITE: Investor Relations Group, Inc.James Carbonara, 212-825-3210orPublic Relations:Susan Morgenbesser/Janet Vasquez, 212-825-3210 Copyright Business Wire 2009 sick pupies . KVISTGARD, Denmark, January 12 /PRNewswire-FirstCall/ -- Bavarian Nordicowns several United States patents relating to an attenuated strain of thecompany's core technology, MVA-BN(R), which is the basis for its smallpoxvaccine, IMVAMUNE(R).

MVA-BN(R) also holds promise as a vector for deliveringrecombinant vaccines . Bavarian Nordic has asserted three US patents as abasis for its infringement action sick pupppies . The claim in this case is that OxfordBioMedica has infringed Bavarian Nordic's patents by commercializing thepatented technology in ways that have yielded large payments fromSanofi-Aventis under the agreement between them for the development andcommercialization of TroVax(R).Oxford BioMedica argues that the law suit is premature because TroVax(R)is still being evaluated in clinical trials.In Bavarian Nordic's patent infringement suit against Oxford BioMedica,in the United States, the Judge has for procedural reasons dismissed thefirst complaint but has encouraged Bavarian Nordic to file a new complaintwithin 14 days, to provide the court with more information sick puppies tour dates 2009 . Bavarian Nordicwill file such a new complaint and thus the case is still pending at thecourt awaiting new information from Bavarian Nordic.If the court eventually should decide to dismiss the suit this decisionwill bear no influence on the substance of the patent case .